Exemple de utilizare a Who develop în Engleză și traducerile lor în Română
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
For many people who develop ARDS it is fatal.
The dose should also be reduced temporarily in patients who develop diarrhoea.
Addressed to people who develop long-term activities.
Discontinuation of vinflunine should be considered in patients who develop cardiac ischaemia.
GOD bless u all who develop this effective site.
Oamenii se traduc, de asemenea,
In addition, in contracts relating to works, services or supplies, the amount of the guarantee andits possible renewal is reduced by 15% for economic operators who develop an inventory of greenhouse gases or a climate footprint.
Children who develop amyloidosis may require a kidney transplant.
Discontinuation of Xtandi in patients who develop PRES is recommended.
The experts who develop these products know what they're doing: trust them.
They will act from a team of scientists who develop research programs.
In patients who develop these symptoms, increasing the dose may be detrimental.
Lynx is a reputable group of modders who develop variations of popular apps.
For patients who develop QTc prolongation, see sections 4.2, 4.8 and 5.2.
Monitoring may help to identify patients who develop cardiac dysfunction.
People with diabetes who develop gastroparesis are diagnosed with diabetic gastroparesis(DG).
Ramucirumab treatment should be discontinued in patients who develop fistula(see section 4.2).
Because it is rare, some who develop Cauda Equina Syndrome are the victims of medical malpractice.
Cabozantinib should be discontinued in patients who develop nephrotic syndrome.
Patients who develop Grade 3 or Grade 4 lymphopenia may continue treatment without interruption.
Discontinue treatment in patients who develop evidence of hepatic decompensation.
Patients who develop a single value of a QTc interval of≥500 msec should stop taking vandetanib.
Crizotinib should be discontinued in patients who develop gastrointestinal perforation.
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Eucreas.
Therapy with Ofev should be permanently discontinued in patients who develop gastrointestinal perforation.
Patients who develop increased transaminase levels should be monitored until the abnormalities have resolved.
Therapy should be permanently discontinued in patients who develop arterial thromboembolic events.
In patients who develop evidence of hepatic decompensation during treatment, Pegasys should be discontinued.
Sunitinib therapy should be discontinued in patients who develop TMA and prompt treatment is required.
Patients who develop angioedema after treatment with zaleplon should not be rechallenged with the active substance.
Sevelamer carbonate treatment should be re-evaluated in patients who develop severe gastrointestinal symptoms.